Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Circassia Pharmaceuticals ( (GB:NIOX) ) is now available.
NIOX Group plc reported a robust financial performance for the year ending December 31, 2024, with a revenue increase of approximately 14% to £41.8 million. The growth was driven by their core Clinical business, with clinical revenue growing by around 11% and research revenue by 33%, benefiting from pharmaceutical studies in asthma and COPD. Despite a decrease in net cash due to a tender offer, the company achieved an adjusted EBITDA slightly above market expectations, indicating strong operational leverage. The company plans to focus on expanding its presence in the USA and developing a home-use product in 2025, with expectations for continued profitable growth.
More about Circassia Pharmaceuticals
NIOX Group plc is a medical device company that focuses on asthma diagnosis, monitoring, and management at the point of care. The company is engaged in the design, development, and commercialization of devices that measure FeNO, a biomarker for asthma, with their leading product being the NIOX VERO®. NIOX operates through a direct sales organization and an extensive distributor network across 50 countries.
YTD Price Performance: -6.35%
Average Trading Volume: 958,170
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £234.5M
Find detailed analytics on NIOX stock on TipRanks’ Stock Analysis page.
